
Press Release

August 5, 2025

Sumitomo Pharma Co., Ltd.

**Notice Regarding the Completion of the CRAFT
Regenerative Medicine and Cell Therapy Manufacturing Facility**

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) today announced that S-RACMO Co., Ltd. (Head Office: Suita, Osaka; President and CEO: Atsushi Tsuchida), the joint venture with and Sumitomo Chemical Co., Ltd. (Head Office: Tokyo, Japan; President: Nobuaki Mito), has completed the construction of the third building of its regenerative medicine and cell therapy manufacturing facility, called “CRAFT” (Center for Regenerative Medicine and Future Therapy). This expansion represents a significant step forward in strengthening S-RACMO’s manufacturing capabilities and supporting the continued growth of its regenerative and cellular medicine business.

Please refer to the attached document for further details.

Contact:

Corporate Communications, Corporate Governance

Sumitomo Pharma Co., Ltd.

E-mail : prir@sumitomo-pharma.co.jp

August 5, 2025
S-RACMO Co., Ltd.

Completion of the CRAFT Regenerative Medicine and Cell Therapy Manufacturing Facility

S-RACMO Co., Ltd. today announced that, to further expand its business, it has completed construction of its third regenerative medicine and cell therapy manufacturing facility, called CRAFT (Center for Regenerative Medicine and Future Therapy) (“the New Facility”).

To contribute to the early spread and commercialization of regenerative medicine and cell therapies, the company develops manufacturing methods and manufactures products for the regenerative medicine and cell therapy field as a contract development and manufacturing organization (CDMO). Starting with the commercial manufacture of regenerative medicine products, up until now, under contract from outside companies, the company has manufactured various types of iPS cells, somatic cells, and somatic stem cells, both autologous and allogeneic cells, for clinical trials, non-clinical uses, and other applications. By constructing the New Facility, in addition to increasing its production capacity for existing products under contract, the company will strengthen its manufacturing organization to meet the needs of customers in and outside of Japan that are developing regenerative medicine and cell therapies.

The New Facility is located on the same premises as the two existing regenerative medicine and cell therapy manufacturing facilities (SMaRT and FORCE), and their design and specifications leverage the know-how and experience gained from operating multiple facilities. Because these facilities have easy access to Osaka International Airport and Kansai International Airport, manufactured regenerative medicine and cell therapies can be quickly shipped outside Japan as well as to major regions throughout Japan.

In addition, the company plans to invest an additional amount of approximately 15 billion yen to augment its production capacity. In addition to augmenting its existing facilities, such as with additional production equipment and testing facilities, the investment plan also includes a fourth regenerative medicine and cell therapy manufacturing facility. The investment will utilize the 2024 Supplementary Budget Expense Subsidies for Manufacturing Equipment for Regenerative Medicine, Cell Therapies, and Gene Therapies ^{*1} program from the Japanese government’s Ministry of Economy, Trade and Industry, its selection for which the company announced earlier. This will further strengthen the company’s manufacturing capacity and accelerate the expansion of its business.

Using the new facility as well as SMaRT and FORCE, the company will engage in contract manufacturing of high-quality regenerative medicine and cell therapies in compliance with the

latest GCTP*² and cGMP*³ standards, thereby contributing to the development and commercialization of customers' regenerative medicine and cell therapies.

*1. The Expense Subsidies for Manufacturing Equipment for Regenerative Medicine, Cell Therapies, and Gene Therapies is a program that provides support for developing CDMOs with contract manufacturing locations in Japan and training manufacturing talent to ensure Japan's capabilities to smoothly manufacture regenerative, cellular, and gene therapies. Among the selected applicants, large enterprises and equivalent organizations can receive subsidies of up to 50% for approved expenses.

Reference: S-RACMO's press release dated July 16, 2025 in Japanese:

“Notice Regarding the Company's Selection for the 2024 Supplementary Budget Expense Subsidies for Manufacturing Equipment for Regenerative Medicine, Cell Therapies, and Gene Therapies”

[「令和 6 年度補正 再生・細胞医療・遺伝子治療製造設備支援事業費補助金」採択について](#)

*2. GCTP: Good Gene, Cellular, and Tissue-based Products Manufacturing Practice

*3. cGMP: current Good Manufacturing Practice

Inquiries:

Corporate Administration Department, S-RACMO Co., Ltd.

Phone: 06-6337-0180

Reference:

Overview of the Facility	
Name:	Regenerative Medicine and Cell Therapy Manufacturing Facility CPC (CRAFT)
Address:	33-94 Enoki-cho, Suita, Osaka, Japan (on the premises of Sumitomo Pharma's Central Research Laboratories)
Business Description:	Develops manufacturing methods and manufactures products for the regenerative medicine and cell therapy field as a contract development and manufacturing organization
Building area:	1,836 square meters (two floors, steel construction)
Construction start:	July 2024
Completion:	July 2025
Specifications:	<ul style="list-style-type: none"> • Multiple suites with independent air conditioning • Compliant with BSL-2 containment level • Manufacturing method study lab and QC testing office in the second floor area

	<ul style="list-style-type: none"> • Carbon neutral initiatives: Air conditioning system deploys energy conservation methods (consumes about one-third less energy than conventional facilities) • All electric, reducing CO2 emissions
Total cost:	Approximately 3.7 billion yen

External view of the CRAFT

